Showing 1 - 5 of 5
In this Q&A, Ian Kimber, Emeritus Professor of Toxicology in the Faculty of Biology, Medicine and Health at the University of Manchester, provides an immunological perspective on current issues impacting upon the life sciences sector, ranging from recently approved cancer drugs to COVID-19 vaccines.
As innovation and new technologies are rapidly transforming the way we live, it is imperative that businesses in all industries remain alive to the risks arising from these advancements.
Our product liability and life sciences team recently hosted their fifth life sciences conference which focused on emerging risks in innovative healthcare technology.
The House of Commons Health and Social Care Committee has published a report on the second phase of its investigation into the impact of Brexit on the life sciences sector.
The European Commission issued a Notice to Stakeholders highlighting the legal and practical implications of a “No Deal” scenario for industrial products placed on the EU-27 market.